Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foralumab - Tiziana Life Sciences

Next Previous
Drug Profile

Foralumab - Tiziana Life Sciences

Alternative Names: NI-0401; NI-0401/α-CD3; TZLS-401

Latest Information Update: 04 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; NovImmune SA
  • Developer Brigham and Women's Hospital; Light Chain Bioscience; NovImmune SA; Tiziana Life Sciences
  • Class Anti-inflammatories; Antidementias; Antihaemorrhagics; Antihyperglycaemics; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Crohn's disease; Multiple sclerosis; Multiple system atrophy
  • Preclinical Amyotrophic lateral sclerosis; Haemorrhage; Obesity; Post acute COVID 19 syndrome; Spinal cord injuries; Traumatic brain injuries; Type 1 diabetes mellitus
  • No development reported Cytokine release syndrome; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Type 2 diabetes mellitus
  • Discontinued Transplant rejection

Most Recent Events

  • 25 Feb 2026 Pharmacodynamics and adverse events data from an Expanded Access Programme in Multiple sclerosis released by Tiziana Life Sciences
  • 12 Dec 2025 Phase-II clinical trials in Alzheimer's disease (Combination therapy, Early-stage disease) in USA (Intranasal) (NCT06489548)
  • 12 Dec 2025 Phase-II clinical trials in Alzheimer's disease (Early-stage disease, Monotherapy) in USA (Intranasal) (NCT06489548)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top